• Consensus Rating: Buy
  • Consensus Price Target: $211.75
  • Forecasted Upside: 24.16%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$170.54
▼ -0.78 (-0.46%)

This chart shows the closing price for ZTS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Zoetis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZTS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZTS

Analyst Price Target is $211.75
▲ +24.16% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Zoetis in the last 3 months. The average price target is $211.75, with a high forecast of $237.00 and a low forecast of $180.00. The average price target represents a 24.16% upside from the last price of $170.54.

This chart shows the closing price for ZTS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in Zoetis. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/21/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/19/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/16/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/14/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/13/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/8/2024HSBCLower TargetBuy ➝ Buy$230.00 ➝ $225.00Low
5/6/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$223.00 ➝ $196.00Low
4/30/2024Stifel NicolausLower TargetBuy ➝ Buy$195.00 ➝ $180.00Low
4/23/2024BarclaysLower TargetOverweight ➝ Overweight$260.00 ➝ $230.00Low
4/16/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$220.00 ➝ $195.00Low
4/2/2024Stifel NicolausLower TargetBuy ➝ Buy$215.00 ➝ $195.00Low
2/20/2024Piper SandlerBoost TargetOverweight ➝ Overweight$215.00 ➝ $220.00Low
2/14/2024BarclaysBoost TargetOverweight ➝ Overweight$255.00 ➝ $260.00Low
1/17/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$190.00 ➝ $226.00Low
1/12/2024Stifel NicolausBoost TargetBuy$195.00 ➝ $215.00Low
12/19/2023Jefferies Financial GroupReiterated RatingBuy$230.00Low
12/7/2023BNP ParibasInitiated CoverageOutperform$237.00Low
11/6/2023Piper SandlerBoost TargetOverweight ➝ Overweight$210.00 ➝ $215.00Low
10/30/2023Stifel NicolausLower TargetBuy ➝ Buy$205.00 ➝ $195.00Low
10/5/2023Piper SandlerLower Target$220.00 ➝ $210.00Low
9/19/2023ArgusBoost Target$190.00 ➝ $201.00Low
9/12/2023Stifel NicolausReiterated RatingBuy ➝ Buy$205.00Low
9/6/2023HSBCInitiated CoverageBuy$230.00Low
8/28/2023Stifel NicolausBoost TargetBuy ➝ Buy$195.00 ➝ $205.00Low
8/14/2023Piper SandlerBoost TargetOverweight ➝ Overweight$210.00 ➝ $220.00Low
8/9/2023The Goldman Sachs GroupBoost TargetBuy ➝ Buy$204.00 ➝ $213.00Low
5/8/2023Piper SandlerLower Target$220.00 ➝ $210.00Low
4/11/2023Bank Of America (Bofa)Boost TargetBuy ➝ Buy$180.00 ➝ $200.00Low
2/21/2023BarclaysBoost TargetOverweight$250.00 ➝ $260.00Low
11/15/2022Morgan StanleyLower TargetOverweight$264.00 ➝ $248.00Low
11/4/2022The Goldman Sachs GroupLower TargetBuy$207.00 ➝ $180.00Low
11/3/2022William BlairReiterated RatingOutperformLow
10/17/2022JPMorgan Chase & Co.Lower TargetOverweight$250.00 ➝ $225.00Low
8/5/2022William BlairReiterated RatingOutperformLow
7/21/2022The Goldman Sachs GroupLower TargetConviction-Buy ➝ Buy$208.00 ➝ $202.00Low
7/11/2022Piper SandlerInitiated CoverageOverweight$205.00N/A
6/24/2022Stifel NicolausLower TargetBuy$275.00 ➝ $225.00Low
5/19/2022The Goldman Sachs GroupLower TargetBuy$237.00 ➝ $208.00Low
3/9/2022CitigroupLower TargetNeutral$232.00 ➝ $208.00High
12/20/2021CitigroupBoost TargetNeutral$184.00 ➝ $232.00Medium
11/18/2021Morgan StanleyInitiated CoverageOverweight$264.00High
11/5/2021BarclaysBoost TargetOverweight$235.00 ➝ $240.00High
8/25/2021ArgusBoost TargetBuy$195.00 ➝ $225.00Low
8/9/2021Credit Suisse GroupBoost TargetOutperform$206.00 ➝ $230.00Low
8/6/2021BarclaysBoost TargetOverweight$208.00 ➝ $235.00Low
7/16/2021Raymond JamesDowngradeOutperform ➝ Market PerformLow
7/13/2021Cantor FitzgeraldBoost TargetOverweight$210.00 ➝ $238.00Low
5/28/2021ArgusBoost TargetBuy$185.00 ➝ $195.00Medium
5/12/2021CitigroupBoost Target$175.00 ➝ $184.00Medium
5/7/2021Raymond JamesBoost TargetOutperform$166.00 ➝ $192.00Medium
5/7/2021BarclaysBoost TargetOverweight$200.00 ➝ $208.00Medium
3/8/2021Raymond JamesUpgradeMarket Perform ➝ Outperform$166.00Medium
3/8/2021Bank of AmericaUpgradeNeutral ➝ Buy$180.00Medium
2/17/2021Credit Suisse GroupBoost Target$197.00 ➝ $203.00Low
11/13/2020Morgan StanleyBoost TargetEqual Weight$167.00 ➝ $174.00Low
11/12/2020Truist FinancialBoost Target$160.00 ➝ $170.00Low
11/6/2020BarclaysBoost TargetOverweight$175.00 ➝ $189.00Medium
9/21/2020Atlantic SecuritiesInitiated CoverageOverweight$191.00Low
8/20/2020Morgan StanleyBoost TargetNeutral ➝ Equal Weight$125.00 ➝ $167.00Low
8/14/2020Edward JonesUpgradeHold ➝ BuyLow
8/12/2020G.ResearchDowngradeBuy ➝ HoldLow
8/12/2020GabelliDowngradeBuy ➝ HoldLow
8/10/2020Truist FinancialBoost TargetNeutral ➝ Hold$112.00 ➝ $160.00Low
8/10/2020CitigroupBoost TargetNeutral$146.00 ➝ $160.00Low
8/7/2020Stifel NicolausBoost TargetTop Pick ➝ Buy$155.00 ➝ $170.00Medium
7/30/2020CitigroupBoost TargetNeutral$131.00 ➝ $146.00Medium
7/20/2020Bank of AmericaBoost TargetNeutral$135.00 ➝ $150.00Medium
6/3/2020ArgusReiterated RatingBuyLow
5/27/2020Jefferies Financial GroupInitiated CoverageBuy$152.00High
5/18/2020Credit Suisse GroupReiterated RatingBuy$147.00High
5/8/2020UBS GroupLower TargetNeutral$146.00 ➝ $126.00Low
5/8/2020CitigroupLower TargetNeutral$139.00 ➝ $131.00Low
5/7/2020BarclaysBoost TargetOverweight$129.00 ➝ $140.00Medium
4/2/2020Morgan StanleyLower TargetEqual Weight$148.00 ➝ $125.00High
3/31/2020G.ResearchUpgradeHold ➝ BuyHigh
2/28/2020The Goldman Sachs GroupReiterated RatingBuy$162.00High
2/19/2020UBS GroupBoost TargetNeutral$126.00 ➝ $146.00Low
2/14/2020Morgan StanleyBoost TargetEqual Weight$136.00 ➝ $148.00Low
2/14/2020SunTrust BanksReiterated RatingHold$145.00Low
2/13/2020CfraUpgradeBuy ➝ Strong-Buy$147.00 ➝ $160.00Low
2/12/2020Bank of AmericaReiterated RatingHold$145.00Medium
1/9/2020Raymond JamesInitiated CoverageMarket PerformLow
12/5/2019Bank of AmericaReiterated RatingHold$125.00Low
10/11/2019Credit Suisse GroupSet TargetBuy$138.00Low
9/30/2019Morgan StanleyBoost TargetHold ➝ Equal Weight$100.00 ➝ $136.00Low
9/13/2019Stifel NicolausSet TargetBuy$140.00Medium
9/11/2019Credit Suisse GroupReiterated RatingBuy$130.00High
9/9/2019The Goldman Sachs GroupInitiated CoverageConviction-Buy$145.00Medium
9/4/2019ArgusSet TargetBuy$140.00Low
8/13/2019SunTrust BanksBoost TargetHold$120.00 ➝ $130.00Low
8/7/2019Craig HallumBoost TargetBuy$132.00 ➝ $138.00Low
8/7/2019BarclaysBoost TargetOverweight$120.00 ➝ $135.00Low
7/22/2019Stifel NicolausBoost TargetBuy$110.00 ➝ $130.00Medium
7/1/2019Bank of AmericaDowngradeBuy ➝ Neutral$111.00 ➝ $120.00Low
6/25/2019Craig HallumBoost TargetBuy$114.00 ➝ $132.00Low
(Data available from 6/14/2019 forward)

News Sentiment Rating

1.17 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/17/2023
  • 30 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/17/2023
  • 22 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/16/2024
  • 34 very positive mentions
  • 32 positive mentions
  • 9 negative mentions
  • 0 very negative mentions
2/15/2024
  • 33 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/16/2024
  • 24 very positive mentions
  • 27 positive mentions
  • 7 negative mentions
  • 10 very negative mentions
4/15/2024
  • 51 very positive mentions
  • 48 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
5/15/2024
  • 34 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/14/2024

Current Sentiment

  • 34 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Zoetis logo
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
Read More

Today's Range

Now: $170.54
Low: $168.89
High: $171.59

50 Day Range

MA: $165.75
Low: $145.54
High: $178.83

52 Week Range

Now: $170.54
Low: $144.80
High: $201.92

Volume

2,225,305 shs

Average Volume

2,969,497 shs

Market Capitalization

$77.82 billion

P/E Ratio

32.86

Dividend Yield

0.98%

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Zoetis?

The following Wall Street analysts have issued research reports on Zoetis in the last twelve months: Argus, Barclays PLC, BNP Paribas, HSBC Holdings plc, Jefferies Financial Group Inc., Piper Sandler, Stifel Nicolaus, StockNews.com, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for ZTS.

What is the current price target for Zoetis?

8 Wall Street analysts have set twelve-month price targets for Zoetis in the last year. Their average twelve-month price target is $211.75, suggesting a possible upside of 24.2%. BNP Paribas has the highest price target set, predicting ZTS will reach $237.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $180.00 for Zoetis in the next year.
View the latest price targets for ZTS.

What is the current consensus analyst rating for Zoetis?

Zoetis currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZTS will outperform the market and that investors should add to their positions of Zoetis.
View the latest ratings for ZTS.

What other companies compete with Zoetis?

How do I contact Zoetis' investor relations team?

Zoetis' physical mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company's listed phone number is (973) 822-7000 and its investor relations email address is [email protected]. The official website for Zoetis is www.zoetis.com. Learn More about contacing Zoetis investor relations.